Pune-based drug discovery research company Novalead will study the effectiveness of an anti- parasitic drug in the recovery of moderately ill Covid-19 patients, according to its CEO.

The Tata Capital-backed company uses computational model to search existing drugs for newer therapies.

Supreet Deshpande, CEO of Novalead, told ET that the firm will start phase 3 randomised trials to study whether the generic drug nitazoxanide brings down the viral load of a moderately ill Covid-1 ..